CCBs Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Calcium Channel Blockers DMPK and Bioanalytical Services

CCB bioanalysis has a single dominant CYP — CYP3A4 — but two distinct analytical identities. Amlodipine, nifedipine, and felodipine act as CYP3A4 substrates requiring standard Phase I MetID workflows. Verapamil and diltiazem are CYP3A4 substrates, CYP3A4 inhibitors, and P-gp substrates, adding DDI risk that pure-substrate methods do not address. A generic CYP3A4 incubation protocol — treating all five as simple substrates — misses the inhibitor dimension entirely.

Creative Proteomics provides CCB-focused DMPK workflows spanning CYP3A4 substrate metabolism and MetID, P-gp-informed disposition studies, CYP3A4 inhibitor-aware DDI risk profiling, and custom multi-CCB panels.

Browse CCB Drug Index Request Custom CCB Method Support

CYP3A4: The Common EnzymeAll five CCBs share CYP3A4 as the primary metabolic route, enabling unified incubation conditions and isoform-specific study design.

Substrate vs Substrate + Inhibitor DualityVerapamil and diltiazem are CYP3A4 substrates AND inhibitors; co-incubated probe substrates require inhibitor-aware controls.

P-gp Disposition RelevanceVerapamil and diltiazem are P-gp substrates, adding transporter-mediated disposition to the CYP3A4 metabolism picture.

CCB CYP3A4 Identity Risks DMPK Strategy Map

⚡

CYP3A4 Substrate ClassificationAmlodipine, nifedipine, and felodipine are CYP3A4 substrates only; verapamil and diltiazem are CYP3A4 substrates AND inhibitors — two distinct analytical identities.

🧬

CYP3A4 Substrate Metabolism & MetIDAmlodipine, nifedipine, and felodipine require standard CYP3A4 Phase I MetID in activity-verified microsome/hepatocyte models.

📊

CYP3A4 Inhibitor-Aware DDI ProfilingVerapamil and diltiazem require substrate metabolism PLUS inhibitor-aware DDI controls to prevent co-incubated probe substrate interference.

🔬

P-gp Transporter DispositionVerapamil and diltiazem are P-gp substrates, adding transporter-mediated disposition questions to the CYP3A4 metabolism picture.

CCB-specific CYP3A4 identity classification.Creative Proteomics determines whether the compound is a CYP3A4 substrate only or a CYP3A4 substrate+inhibitor before method development — because co-incubating a CYP3A4 inhibitor with probe substrates produces DDI artifacts that pure-substrate workflows do not detect.

CCB Drug Index

Find the CCB Compound Behind the Study

CCB studies split by a key analytical question: is the compound a CYP3A4 substrate only, or a CYP3A4 substrate plus inhibitor with P-gp transport and DDI risk? Use the index to classify the DDI profile and route the workflow accordingly. The drug panels are intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only CCBs matching all selected values.

5 entries · Page 1 of 3

Analytical Pain Points

What Drives Assay Failure in CCB Studies?

CCBs fail analytically not because CYP3A4 is hard to detect, but because verapamil and diltiazem are CYP3A4 inhibitors — a single incubation method that works for amlodipine/nifedipine/felodipine as pure substrates will confound DDI study results when the test compound itself inhibits the probe substrate.

Substrate + Inhibitor Duality Demands Two Workflows

Amlodipine, nifedipine, and felodipine require CYP3A4 substrate-only MetID. Verapamil and diltiazem require CYP3A4 substrate metabolism plus inhibitor-aware DDI profiling. One β-NADPH-supplemented microsome protocol cannot serve both analytical identities.

Our responseCCB-class-aware workflows that classify each compound as CYP3A4 substrate or CYP3A4 substrate+inhibitor before method development begins.

LC-MS/MS Drug Quantification →

DDI Risk from Co-Incubated Probe Substrate Competition

When verapamil or diltiazem is incubated alongside a CYP3A4 probe substrate, competitive CYP3A4 inhibition suppresses probe metabolism — producing falsely elevated DDI risk readings that reflect the CCB’s own inhibitor property rather than the test drug under investigation.

Our responseInhibitor-aware DDI study design with sequential incubation protocols and IC₅₀-calibrated probe concentration adjustment for substrate+inhibitor CCBs.

CYP Inhibition Assays →

P-gp Substrate Status Adds Transporter-Mediated Disposition

Verapamil and diltiazem are dual CYP3A4-P-gp substrates, meaning hepatic metabolism and P-gp efflux interact to determine systemic exposure. Pure-substrate methods that ignore P-gp disposition may misinterpret concentration data.

Our responseP-gp-informed bioanalysis with transporter substrate classification and disposition-context reporting for verapamil and diltiazem.

Complex Biological Matrices →

CYP3A4 Isoform Activity Variability Across Microsome Batches

All five CCBs depend on CYP3A4 activity. Inter-batch variability in microsome CYP3A4 expression level — even from the same vendor — introduces systematic bias in substrate depletion and metabolite formation rates.

Our responseCYP3A4 activity-verified microsome and hepatocyte batches with isoform-specific activity normalization before incubation.

Metabolite Identification →

Multi-CCB Panels Must Accommodate Inhibitor-Substrate Conflict in One Assay

A panel containing both pure substrates (amlodipine, nifedipine, felodipine) and substrate+inhibitors (verapamil, diltiazem) requires inhibitor-compensated incubation conditions, separate DDI readouts, and substrate-inhibitor separation at the method design stage.

Our responseCustom multi-CCB panels with incubation conditions validated for mixed substrate-inhibitor analyte sets and separate DDI probe arms.

Custom Panels →

Focused Service Paths

Four Practical Routes for CCB Studies

CCB workflows should be selected according to CYP3A4 identity: substrate-only MetID for amlodipine, nifedipine, and felodipine; substrate+inhibitor DDI profiling for verapamil and diltiazem; P-gp-informed disposition studies for dual CYP3A4-P-gp substrates; or multi-CCB panels for mixed-identity study designs.

CYP3A4 Substrate Metabolism & MetID

For amlodipine, nifedipine, and felodipine — Phase I CYP3A4-mediated metabolism and metabolite identification in microsome and hepatocyte models.

Phase I metabolite profiling
CYP3A4 isoform-specific incubation
Activity-verified microsome/hepatocyte selection
Substrate depletion and metabolite kinetics

Metabolite Identification →

CYP3A4 Inhibitor-Aware DDI Risk Profiling

For verapamil and diltiazem — CYP3A4 substrate metabolism combined with inhibitor-aware DDI study design to separate substrate depletion from probe-substrate inhibition.

IC₅₀-based inhibitor classification
Sequential vs co-incubation protocol selection
Probe substrate concentration adjustment
Substrate + inhibitor dual-readout reporting

DDI Screening Services →

P-gp Transporter Disposition Studies

For verapamil and diltiazem — P-gp substrate transport assessment and CYP3A4-P-gp interplay in hepatic disposition.

P-gp substrate classification
CYP3A4 metabolism + P-gp efflux dual profiling
Transporter-informed exposure interpretation

Complex Biological Matrices →

Custom Multi-CCB Panel Development

For studies combining pure CYP3A4 substrates with substrate+inhibitor CCBs in one validated method.

Substrate-inhibitor compatibility assessment
Incubation condition optimization
DDI probe arm separation
Panel-level extraction and MRM scheduling

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted CCB?

If you are working with a CCB requiring CYP3A4 substrate-only MetID, a CYP3A4 substrate+inhibitor compound needing DDI risk profiling, a P-gp substrate requiring transporter disposition analysis, or a multi-CCB panel, standard parent-only methods may miss the inhibitor dimension.

Creative Proteomics designs custom CCB workflows by defining CYP3A4 substrate or substrate+inhibitor status, P-gp transport relevance, DDI risk profile, biological matrix, and panel composition before method development.

Target CCB

Substrate only or substrate + inhibitor

CYP3A4 isoform

P-gp transport status

DDI risk profiling need

Panel requirements